The short version of clinical development fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-08 and is reviewed periodically as new material appears.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
=== Relation to athletic performance === Polycythemia is theorized to increased performance in endurance sports due to the blood being able to store more oxygen. This idea has led to the illegal use of blood doping and transfusions among professional athletes, as well as use of altitude training or elevation training masks to simulate a low-oxygen environment. However, the benefits of altitude training for athletes to improve sea-level performance are not universally accepted, with one reason being athletes at altitude might exert less power during training.
Flap endonuclease (FEN) is an endonuclease that catalyzes structure-specific cleavage. This cleavage is highly sensitive to mismatches and can be used to interrogate SNPs with a high degree of specificity In the basic Invader assay, a FEN called cleavase is combined with two specific oligonucleotide probes, that together with the target DNA, can form a tripartite structure recognized by cleavase. The first probe, called the Invader oligonucleotide is complementary to the 3’ end of the target DNA. The last base of the Invader oligonucleotide is a non-matching base that overlaps the SNP nucleotide in the target DNA. The second probe is an allele-specific probe which is complementary to the 5’ end of the target DNA, but also extends past the 3’ side of the SNP nucleotide. The allele-specific probe will contain a base complementary to the SNP nucleotide. If the target DNA contains the desired allele, the Invader and allele-specific probes will bind to the target DNA forming the tripartite structure. This structure is recognized by cleavase, which will cleave and release the 3’ end of the allele-specific probe. If the SNP nucleotide in the target DNA is not complementary to the allele-specific probe, the correct tripartite structure is not formed and no cleavage occurs. The Invader assay is usually coupled with fluorescence resonance energy transfer (FRET) system to detect the cleavage event. In this setup, a quencher molecule is attached to the 3’ end and a fluorophore is attached to the 5’ end of the allele-specific probe.
== Biosynthesis and industrial production == Tryptophan is not synthesized from simpler substances in humans and other animals and is sourced from dietary intake of tryptophan-containing proteins. Plants and microorganisms commonly synthesize tryptophan from shikimic acid or anthranilate. Tryptophan biosynthesis starts with the condensation of anthranilate with phosphoribosylpyrophosphate (PRPP), generating pyrophosphate as a by-product. The ring of the ribose moiety is opened and subjected to reductive decarboxylation, producing indole-3-glycerol phosphate; this, in turn, is transformed into indole. In the last step, tryptophan synthase catalyzes the formation of tryptophan from indole and the amino acid serine.
He also vetoed the "Green Giant", a skyscraper on the South Bank, initiated plans for the National Gallery extension (the winning entry was famously described by Prince Charles as "a monstrous carbuncle" and was never built) and signed off on the building of the Queen Elizabeth II Centre on a bomb site near Westminster; when he was unable to secure private funding as planned the Treasury were forced to pay for the building. Some of the DoE's responsibilities were hived off into English Heritage, a new body.
Sources: en.wikipedia.org
Lawsone (2-hydroxy-1,4-naphthoquinone), also known as hennotannic acid, is a red-orange dye present in the leaves of the henna plant (Lawsonia inermis), for which it is named, as well as in the common walnut (Juglans regia) and water hyacinth (Pontederia crassipes). Humans have used henna extracts containing lawsone as hair and skin dyes for more than 5,000 years. Lawsone reacts chemically with the protein keratin in skin and hair via a Michael addition reaction, resulting in a strong permanent stain that lasts until the skin or hair is shed. Darker colored staining is due to more lawsone–keratin interactions occurring, which evidently break down as the concentration of lawsone decreases and the tattoo fades. Lawsone strongly absorbs UV light, and aqueous extracts can be effective sunless tanning agents and sunscreens. Lawsone is a 1,4-naphthoquinone derivative, an analog of hydroxyquinone containing one additional ring. Lawsone isolation from Lawsonia inermis can be difficult due to its easily biodegradable nature. Isolation involves four steps:
== RNA-DNA world == In 2020, coevolution of a RNA-DNA mixture based on diamidophosphate was proposed. The mixture of RNA-DNA sequences, called chimeras, have weak affinity and form weaker duplex structures. This is advantageous in an abiotic scenario and these chimeras have been shown to replicate RNA and DNA – overcoming the "template-product" inhibition problem, where a pure RNA or pure DNA strand is unable to replicate non-enzymatically because it binds too strongly to its partners. This could lead to an abiotic cross-catalytic amplification of RNA and DNA. A continuous chemical reaction network in water and under high-energy radiation can generate precursors for early RNA. In 2022, evolution experiments of self-replicating RNA showed how RNA may have evolved to diverse complex molecules in RNA world conditions. The RNA evolved to a "replicator network comprising five types of RNAs with diverse interactions" such as cooperation for replication of other members (multiple coexisting host and parasite lineages).
Melo's government also became known for his large-scale program of the concession of programs and public spaces to private initiatives, saying that the privatization program "is in the DNA" of his government. It was put forth that the municipality did not have the conditions to maintain these services adequately and that the partnerships would bring qualified individuals to the system and health benefits for the population. During his electoral campaign, he declared that services should be public, but backed up by private partnerships. Places for the dispersion of the equipment included Auditório Araújo Viana, Teatro de Câmara Túlio Piva, Parque da Harmonia, and stretch 1 of the Orla do Guaíba, some of them completing a process started during the previous administration. They had expected new concessions at Farroupilha, Moinhos de Vento and Marinha do Brasil parks; from stretches 2 and 3 of the Orla do Guaíba; Hospital de Pronto Socorro and Hospital Materno-Infantil Presidente Vargas; the Usina do Gasômetro; with garbage collection and water and sewage treatment; green areas in the surrounding areas of the Aeromóvel and the area around the Joaquim Felizardo Museum of Porto Alegre. The public transport company Carris was privatized, with its assets being sold. The program came to be criticized for devaluing the public character of services and spaces, and to allow them to be exploited commercially, along with the program's proposals having little transparency and without the necessary dialogue with the community.
In theory, "an allergen must have at least 2 IgE-binding epitopes, and each epitope must be at least 15 amino acid residues long, to trigger a type 1 hypersensitivity reaction." Experiments also show that this degree of hydrolysis is sufficient to not trigger IgE binding from GP19S-allergic patients. Allergenicity of eHVP depends on the specific food source and the enzyme used. Alcalase is able to render chickpea and green pea completely non-immunoreactive but papain only achieves partial reduction. Alcalase is also unable to make white beans non-reactive due to the antinutritional factors preventing complete digestion. Alcalase, but not "Flavourzyme" (a commercial Aspergillus oryzae protease blend for eHVP production), is able to make roasted peanut non-reactive.
=== Heredity === Hyperandrogenism can appear as a symptom of many different genetic and medical conditions. Some of the conditions with hyperandrogenic symptoms, including PMOS, may sometimes be hereditary. Additionally, it is thought that epigenetics may contribute to the pathogenesis of polyendocrine metabolic ovarian syndrome. One potential cause of PMOS is maternal hyperandrogenism, whereby hormonal irregularities in the mother can affect the development of the child during gestation, resulting in the passing of polyendocrine metabolic ovarian syndrome from mother to child. However, no androgen elevations were found in the umbilical cord blood of children born to mothers with PMOS.
Sources: en.wikipedia.org
== Cabinet formation == On March 6 the Cabinet Division issued the de-notification of the caretaker cabinet. The next day PML-N leader Attaullah Tarar said that the federal cabinet would be finalized within the next 48 hours. Adding that HBL President Muhammad Aurangzeb would be considered for the financial portfolio, remarking “The most important portfolio is the finance ministry as the economy has to be revived and the matters with the IMF will have to be taken forward." Shehbaz Sharif would host a dinner together with leaders of the Pakistan Peoples Party (PPP), the Pakistan Muslim League-Quaid (PML-Q), the Istehkam-e-Pakistan Party (IPP) and the Muttahida Qaumi Movement-Pakistan (MQM-P) over Federal Cabinet finalization. PML-N would request for the PPP to join the cabinet, however Bilawal Bhutto would announce that it would support PML-N in government formation without joining cabinet, addressing PPP's CEC meeting “The PPP has decided that while we are not in a position to join the federal government ourselves, nor will we be interested in taking ministries in such a set-up, we also do not want to see political chaos in the country. We do not want to see perpetual crisis in the country,” he said. On March 9 Nawaz Sharif directed Shehbaz Sharif to implement the parties manifesto after the formation of the federal cabinet. Later Nawaz would direct the PM to keep the federal cabinet small in the initial phase. During the meeting, Shehbaz Sharif would table the proposed names of the Federal Cabinet to the PML-N leader.
Inhibitors disrupt the interaction between enzyme and substrate, slowing down the rate of a reaction. There are different types of inhibitor, including both reversible and irreversible forms. Competitive inhibitors are inhibitors that only target free enzyme molecules. They compete with substrates for free enzyme acceptor and can be overcome by increasing the substrate concentration. They have two mechanisms. Competitive inhibitors usually have structural similarities to the substrates and or ES complex. As a result, they can fit into the active site and trigger favourable interactions to fill in the space and block substrates from entry. They can also induce transient conformational changes in the active site so substrates cannot fit perfectly with it. After a short period of time, competitive inhibitors will drop off and leave the enzyme intact. Inhibitors are classified as non-competitive inhibitors when they bind both free enzyme and ES complex. Since they do not compete with substrates for the active site, they cannot be overcome by simply increasing the substrate concentration. They usually bind to a different site on the enzyme and alter the 3-dimensional structure of the active site to block substrates from entry or leaving the enzyme. Irreversible inhibitors are similar to competitive inhibitors as they both bind to the active site. However, irreversible inhibitors form irreversible covalent bonds with the amino acid residues in the active site and never leave. Therefore, the active site is occupied and the substrate cannot enter.
=== Aminoacyl-tRNA synthetase === Each of the 20 amino acids are recognized by its specific aminoacyl-tRNA synthetase. The synthetases are usually composed of one to four protein subunits. The enzymes vary considerably in structure although they all perform the same type of reaction by binding ATP, one specific amino acid and its corresponding tRNA. The most important activity of the aminoacyl-tRNA synthetase is to attach an amino acid to a tRNA, that can then interact with codons that identify its amino acid. Taking both similar acetylation function and amino acid motifs into consideration, 2 separate classes of aminoacyl-tRNA synthetases could be differentiated. Class I enzyme is normally monomeric and binds the tRNA acceptor stem from the minor groove. It adds amino acid to 2’-OH of the adenylate residue, moving it into the 3’-OH position. Meanwhile, Class II aminoacyl-tRNA synthetase is oligomeric and binds the tRNA acceptor stem from the major groove. The enzyme proceeds to add amino acid to the 3’-OH position directly. The aminoacyl-tRNA synthetases can distinguish between different tRNAs and this recognition doesn't follow the same pattern. An aminoacyl-tRNA synthetase recognizes a set of sequentinal elements and binds tRNA with the respective amino acid. Examples of these elements vary: 1 base in the anticodon, 1 of 3 base pairs in the acceptor stem and others. However, depending on the chirality of the amino acid, an aminoacyl-tRNA-synthase can actually disrupt the ester bond between D-amino acids and tRNA.
Myofascial pain syndrome (MPS), also known as chronic myofascial pain (CMP), is a syndrome characterized by chronic pain in multiple myofascial trigger points ("knots") and fascial (connective tissue) constrictions. It can appear in any body part. Symptoms of a myofascial trigger point include: focal point tenderness, reproduction of pain upon trigger point palpation, hardening of the muscle upon trigger point palpation, pseudo-weakness of the involved muscle, referred pain, and limited range of motion following approximately 5 seconds of sustained trigger point pressure. The cause is believed to be muscle tension or spasms within the affected musculature. However, emerging evidence suggests that fascial tissue and its biomechanical and neurophysiological properties may also contribute to the development and persistence of myofascial pain. Diagnosis is based on the symptoms and possible sleep studies. Treatment may include pain medication, physical therapy, mouth guards, and occasionally benzodiazepine. It is a relatively common cause of temporomandibular pain.
Debbie Dingell official U.S. House website Debbie Dingell for Congress Biography at the Biographical Directory of the United States Congress Financial information (federal office) at the Federal Election Commission Legislation sponsored at the Library of Congress Profile at Vote Smart Appearances on C-SPAN
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.